[CNAT] Conatus Pharmaceuticals Inc.
Overview
Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization:
Exchange: NASDAQ
The data is delayed by 15 minutes.
Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max
Chart type: absolute | relative to S&P
Description: Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products include Emricasan, an orally active pan-caspase protease inhibitor for the treatment of acute-on-chronic liver failure; chronic liver failure; post liver transplant clearance of hepatitis C virus infection with sustained viral response; non-alcoholic steatohepatitis; and nonalcoholic fatty liver disease. The company was founded in 2005 and is headquartered in San Diego, California.
See how to gain 20% in 14 sec with TrendsInvesting
Fundamental Ratios
| Shares Outstanding | EPS | EPS Growth - 4 Quarters | EPS Growth - Q/Q | ||||
| EPS Growth - Y/Y | Sales Growth - 4 Quarters | Sales Growth - Q/Q | P/E | ||||
| P/E To EPS Growth | P/S | P/BV | Price/Cash Per Share | ||||
| Price/Free Cash Flow | ROA | -71.33% | ROE | -82.04% | ROI | ||
| Current Ratio | 10.09 | Quick Ratio | Long Term Debt/Equity | 0.04 | Debt Ratio | 0.11 | |
| Gross Margin | Operating Margin | Net Profit Margin | Dividend Payout Ratio | ||||
| Dividend Yield |
Fundamental Data
| Cash From Financing Activities | -30 K | Cash From Investing Activities | 4.37 M | Cash From Operating Activities | -5.95 M | Gross Profit | |
| Net Profit | -5.98 M | Operating Profit | -5.96 M | Total Assets | 32.32 M | Total Current Assets | 31.54 M |
| Total Current Liabilities | 3.13 M | Total Debt | 1000 K | Total Liabilities | 4.22 M | Total Revenue |
Technical Data
| High 52 week | 7.5 | Low 52 week | 3.3 | Last close | 3.99 | Last change | -1.48% |
| RSI | 25.76 | Average true range | 0.23 | Beta | 1.35 | Volume | 6.13 M |
| Simple moving average 20 days | -8.38% | Simple moving average 50 days | -10.25% | Simple moving average 200 days | -14.59% |
Performance Data
| Performance Week | -4.09% | Performance Month | -12.69% | Performance Quart | 8.42% | Performance Half | -28.24% |
| Performance Year | -25.97% | Performance Year-to-date | -13.64% | Volatility daily | 2.66% | Volatility weekly | 5.95% |
| Volatility monthly | 12.2% | Volatility yearly | 42.25% | Relative Volume | 56874.5% | Average Volume | 524.58 K |
| New High | New Low |
News
2019-05-24 09:39:55 | How Many Conatus Pharmaceuticals Inc. NASDAQ:CNAT Shares Do Institutions Own?
2019-05-06 14:53:06 | Conatus' CNAT Earnings, Revenues Miss Estimates in Q1
2019-05-02 19:15:11 | Conatus Pharmaceuticals CNAT Reports Q1 Loss, Lags Revenue Estimates
2019-05-02 18:11:35 | Conatus: 1Q Earnings Snapshot
2019-04-30 07:30:00 | Conatus Pharmaceuticals Announces Publication Demonstrating that Emricasan Ameliorates Portal Hypertension, Improves Liver Structure and Function in a Preclinical Model of Advanced Cirrhosis
2019-04-24 10:33:02 | Conatus Pharmaceuticals CNAT May Report Negative Earnings: Know the Trend Ahead of Q1 Release
2019-04-15 07:30:00 | Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension
2019-04-07 17:04:02 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
2019-04-07 09:30:01 | Why Is Conatus CNAT Down 37.8% Since Last Earnings Report?
2019-04-02 07:30:00 | Conatus Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference
2019-03-27 10:55:02 | Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL
2019-03-22 17:43:09 | Conatus CNAT Declines on Failure of NASH Fibrosis Study
2019-03-22 10:49:15 | Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo
2019-03-21 16:05:00 | Conatus Announces Top-line Results from ENCORE-NF Phase 2b Clinical Trial in NASH Fibrosis
2019-03-20 11:10:03 | Conatus CNAT Focuses on Developing NASH Candidate Emricasan
2019-03-13 10:35:02 | Implied Volatility Surging for Conatus CNAT Stock Options
2019-03-13 09:00:00 | Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension
2019-03-11 10:57:02 | Conatus' CNAT Q4 Earnings Top Estimates, Emricasan in Focus
2019-03-08 20:24:59 | Edited Transcript of CNAT earnings conference call or presentation 8-Mar-19 9:30pm GMT
2019-03-08 16:05:00 | Conatus Pharmaceuticals Reports 2018 Financial Results and Program Updates
2019-03-01 07:30:00 | Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results
2019-02-25 13:20:41 | Is Conatus Pharmaceuticals Inc.’s NASDAQ:CNAT CEO Pay Justified?
2019-02-13 15:36:08 | Conatus CNAT Completes Enrollment in Phase II NASH Study
2019-02-12 07:30:00 | Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis
2019-01-30 08:05:00 | Today's Research Reports on Trending Tickers: Voyager Therapeutics and Conatus Pharmaceuticals
2019-01-29 10:05:03 | Can GW Pharmaceuticals GWPH Deliver a Beat in Q1 Earnings?
2019-01-28 07:30:00 | Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials
2018-12-28 17:40:10 | Conatus CNAT Focuses on Developing NASH Candidate Emricasan
2018-12-13 09:26:02 | The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
2018-12-12 10:03:03 | Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate
2018-12-07 08:04:52 | The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut
2018-12-06 14:51:07 | Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study
2018-12-06 14:13:00 | Shares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpoint
2018-12-06 07:00:00 | Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Exelixis
2018-12-05 07:30:00 | Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis
2018-11-16 10:42:47 | When Will Conatus Pharmaceuticals Inc NASDAQ:CNAT Become Profitable?
2018-11-16 07:50:00 | Investor Expectations to Drive Momentum within 2U, Broadwind Energy, Nuverra Environmental Solutions, Ability, ContraFect, and Conatus Pharmaceuticals — Discovering Underlying Factors of Influence
2018-11-14 08:46:01 | Do Options Traders Know Something About Conatus CNAT Stock We Don't?
2018-11-08 07:30:00 | Conatus Pharmaceuticals Announces Presentations and Posters at AASLD Annual Meeting
2018-11-02 12:30:04 | Conatus' CNAT Q3 Loss In Line, Revenues Lag Estimates
2018-11-02 12:13:05 | Edited Transcript of CNAT earnings conference call or presentation 1-Nov-18 8:30pm GMT
2018-11-02 07:30:11 | Conatus Pharmaceuticals CNAT Reports Q3 Loss, Misses Revenue Estimates
2018-11-02 05:03:24 | Conatus: 3Q Earnings Snapshot
2018-11-01 16:05:00 | Conatus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Program Updates
2018-10-25 07:30:00 | Conatus Pharmaceuticals to Report Third Quarter 2018 Financial Results
2018-10-22 08:00:00 | Today’s Research Reports on Stocks to Watch: Planet Green and The9 Limited
2018-10-11 08:51:12 | Options Traders Expect Huge Moves in Conatus Pharmaceuticals CNAT Stock
2018-10-02 16:05:00 | Conatus Pharmaceuticals Announces Three Accepted Abstracts for AASLD Annual Meeting
2018-09-25 08:00:00 | Conatus Pharmaceuticals, Upcoming Presentations, Analysts Review and Target
2018-09-20 07:30:00 | Conatus Pharmaceuticals to Host Analyst and Investor Symposium on Portal Hypertension